Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Allergic Fungal Rhinosinusitis (Post‑surgery)
CTR20210240Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of dupilumab in allergic fungal rhinosinusitis (AFRS), sponsored by Sanofi. Started Feb 2021; status: completed.
02
Drugs
03
Conditions
allergic fungal rhinosinusitis (AFRS)
Beyond the preview
Go deeper on CTR20210240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210240.